Genelux Corporation is a late-stage biopharmaceutical company developing oncolytic viral immunotherapies using modified vaccinia virus to selectively kill tumor cells and trigger immune responses against patient-specific cancer neoantigens. The company's lead product candidate, Olvi-Vec, is an engineered vaccinia strain in clinical trials for platinum-resistant ovarian cancer, non-small cell lung cancer, and small cell lung cancer, with the potential to address multiple aggressive tumor types through various delivery routes. Genelux generates revenue through licensing agreements with development partners in Asian territories, who fund clinical and commercial activities in exchange for milestone payments and royalties, while retaining U.S. development and commercialization rights to build an internal oncology-focused commercial organization upon regulatory approval.